T cell mediated immunotherapy for B cell lymphoma

Journal of Molecular Medicine

Volumn 77, Issue 3, 1999, Pages 322-331

  Schultze, Joachim L ^a,b   Nadler, Lee M ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CD40 CTL; Idiotype; Lymphoma; Vaccination

Indexed keywords

ANIMAL MODEL; ANTIGEN PRESENTATION; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0033039444     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050358     Document Type: Review

References (135)

1. Rohatiner A, Lister TA (1994) Management of follicular lymphoma. Curr Opin Oncol 6:473-479
2. Shepherd JD, Phillips GL (1993) High-dose therapy for lymphoma. Curr Opin Oncol 5:797-804
3. Straneo M, Gianni L (1994) New active drugs in the treatment of lymphomas. Curr Opin Oncol 6:480-488
4. von Gunten CF, Gordon LI (1993) Treatment of advanced, aggressive non-Hodgkin's lymphoma. Curr Opin Oncol 5:791-796
5. Pardoll DM (1994) A new look for the 1990s. Nature 369:357-358
6. Pardoll DM (1993) Cancer vaccines. Immunol Today 14:310-313
7. Krolick KA, Isakson PC, Uhr JW, Vitetta ES (1979) BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev 48:81-106
8. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878
9. Yefenof E, Picker LJ, Scheuermann RH, Vitetta ES, Street NE, Tucker TF, Uhr JW (1993) Induction of B cell tumor dormancy by anti-idiotypic antibodies. Curr Opin Immunol 5:740-744
10. Old LJ (1992) Tumor immunology: the first century. Curr Opin Immunol 4:603-607
11. Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA (1992) The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 10:33-40
12. Mulligan RC (1993) The basic science of gene therapy. Science 260:926-932
13. Grossbard ML, Fidias P (1995) Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Clin Immunol Immunopathol 76:107-114
14. Waldmann TA (1992) Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. Annu Rev Immunol 10:675-704
15. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg JG-L, A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466
16. Press OW, Appelbaum FR, Eary JF, Bernstein ID (1995) Radiolabeled antibody therapy of lymphomas. Important Adv Oncol 157-171
17. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179-209
18. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24
19. Storkus WJ, Zeh HJ, 3d, Salter RD, Lotze MT (1993) Identification of T-cell epitopes: rapid isolation of class I- presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol 14:94-103
20. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
21. Gross G, Levy S, Levy R, Waks T, Eshhar Z (1995) Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochem Soc Trans 23:1079-1082
22. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373
23. Bogen B, Weiss S (1993) Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol 10:337-355
24. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE (1995) Idiotype DNA vaccines against B-cell lymphoma. Immunol Rev 145:211-228
25. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Thompsett A, Hawkins RE (1995) A genetic approach to idiotypic vaccination for B cell lymphoma. Ann N Y Acad Sci 772:212-226
26. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R (1990) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029-1036
27. George AJ, Tutt AL, Stevenson FK (1987) Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 138:628-634
28. George AJ, Folkard SG, Hamblin TJ, Stevenson FK (1988) Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 141:2168-2174
29. Kwak LW, Young HA, Pennington RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972-10977
30. Kwak LW, Campbell MJ, Zelenetz AD, Levy R (1991) Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood 78:2768-2772
31. Kwak LW, Campbell M, Levy R (1991) Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect Prev 15:323-325
32. Kwak LW, Campbell MJ, Zelenetz AD, Levy R (1990) Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor- derived idiotypic immunoglobulin. Blood 76:2411-2417
33. Kwak LW, Pennington R, Longo DL (1996) Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 87:3053-3060
34. Dyke RJ, McBride H, George AJ, Hamblin TJ, Stevenson FK (1991) Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell Immunol 132:70-83
35. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF (1995) Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 25:3079-3086
36. Wilson A, George AJ, King CA, Stevenson FK (1990) Recognition of a B cell lymphoma by anti-idiotypic T cells. J Immunol 145:3937-3943
37. King CA, Wills MR, Hamblin TJ, Stevenson FK (1993) Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 147:411-424
38. Weiss S, Bogen B (1991) MHC class II-restricted presentation of intracellular antigen. Cell 64:767-776
39. Weiss S, Bogen B (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 86:282-286
40. Lauritzsen GF, Weiss S, Dembic Z, Bogen B (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700-5704
41. Lauritzsen GF, Bogen B (1993) The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148:177-188
42. Lauritzsen GF, Weiss S, Bogen B (1993) Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 37:77-85
43. Lauritzsen GF, Bogen B (1991) Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type. Scand J Immunol 33:647-656
44. Bogen B, Dembic Z, Weiss S (1993) Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J 12: 357-363
45. Vuist WM, Levy R, Maloney DG (1994) Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899-906
46. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype- negative variant cells. Blood 80:1502-1510
47. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R (1993) Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci 690:385-387
48. Stevenson FK (1992) Update on tumor vaccines. Int J Clin Lab Res 22:84-89
49. Stevenson FK, George AJ, Glennie MJ (1990) Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol 48:126-166
50. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209-1215
51. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016-1020
52. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM (1996) Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580-589
53. Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758
54. Chen TT, Tao MH, Levy R (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775-4787
55. Chen TT, Levy R (1995) Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J Immunol 154:3105-3117
56. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58
57. Syrengelas AD, Chen TT, Levy R (1996) DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038-1041
58. Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R (1991) Ig VH gene expression among human follicular lymphomas. Blood 78:1561-1568
59. Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R (1990) Idiotypic variation in a human B lymphoma cell line. J Immunol 144:752-758
60. Zelenetz AD, Chen TT, Levy R (1992) Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 176:1137-1148
61. George AJ, Foreman RC, Stevenson FK (1991) Characterisation of a light chain loss variant of the BCL1 lymphoma. Mol Immunol 28:789-799
62. Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S, et al (1991) Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol 2 Suppl 2:115-122
63. George AJ, Spellerberg MB, Stevenson FK (1988) Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics. J Immunol 140:1695-1701
64. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-3282
65. Schultze JL, Nadler LM, Gribben JG (1996) B7-mediated costimulation and the immune response. Blood Rev 10:111-127
66. Sharpe AH (1995) Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr Opin Immunol 7:389-395
67. Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 248:1349-1356
68. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VAJ, Lombard LA, Gray GS, Nadler LM (1993) Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909-911
69. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM (1991) Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1991:6586-6590
70. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA (1991) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721-730
71. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216
72. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Goldstein P (1987) A new member of the immunoglobulin superfamily CTLA-4. Nature 328:267-269
73. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569
74. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H, et al (1992) CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 149:3795-3801
75. Allison JP, Krummel MF (1995) The yin and yang of T cell costimulation. Science 270:932-933
76. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Jr, Ke X, Gray GS, et al (1995) CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 92:811-815
77. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783-788
78. Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK (1995) Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 155:1032-1036
79. Krummel MF, Sullivan TJ, Allison JP (1996) Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8:519-523
80. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540
81. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465
82. Tivol EA, Bordello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
83. Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541-2550
84. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
85. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736
86. Dranoff G, Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417-454
87. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6:722-727
88. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
89. Van Pel A, van der Bruggen P, Coulie P, Brichard V, Lethe B, Van den Eynde B, Uyttenhove C, Renauld J-C, Boon T (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229-250
90. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687-5690
91. Chen L, Linsley PS, Hellstrom KE (1993) Costimulation of T cells for tumor immunity. Immunol Today 14:483-486
92. Harding FA, Allison JP (1993) CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177:1791-1796
93. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858-3865
94. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370
95. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T- cell responses. Curr Opin Immunol 7:682-686
96. Hellstrom KE, Hellstrom I, Chen L (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145:123-145
97. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523-532
98. Huang AY, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183:769-776
99. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415-1421
100. Huang AY, Bruce AT, Pardoll DM, Levitsky HI (1996) In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4:349-355
101. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I- restricted tumor antigens. Science 264:961-965
102. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S (1995) Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619-629
103. Topalian SL (1994) MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 6:741-745
104. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD (1996) B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 156:1126-1131
105. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD (1995) Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507-2515
106. Gajewski TF, Fallarino F, Uyttenhove C, Boon T (1996) Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 156:2909-2917
107. Gajewski TF (1996) B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 156:465-472
108. 107a. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM (1997). In vivo expression of B7-1 and B7-2 on follicular lymphoma is not sufficient to productively activate T cells in vitro but is sufficient to prevent T cell anergy. Blood 90:4297-4306
109. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM (1994) In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 83:793-798
110. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM (1995) Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200-8204
111. Reference deleted
112. Croft M, Bradley LM, Swain SL (1994) Naive versus memory CD4\T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 152:2675-2685
113. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH (1992) Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360:266-268
114. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Vankooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12:881-922
115. Faassen AE, Dalke DP, Berton MT, Warren WD, Pierce SK (1996) CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur J Immunol 25:3249-3255
116. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM (1997) Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89:3806-3816
117. Lanzavecchia A (1993) Identifying strategies for immune intervention. Science 260:937-944
118. Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068
119. Arvanitakis L, Yaseen N, Sharma S (1995) Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol 155:1047-1056
120. Kopper L, Ladanyi A, Mihalik R, Nagy P (1994) Loss of transforming growth factor beta 1 regulatory activity in human non Hodgkin lymphomas. Antican Res 14:119-122
121. Murase T, Jirtle RL, McDonald GB (1994) Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation. Blood 83:2383
122. Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Sing G, Longo DL, Wiltrout RH, Keller JR (1991) In vivo and in vitro effects of TGF-beta 1 on normal and neoplastic haemopoiesis. Ciba Found Symp 157:212-227; discussion 227
123. Warner GL, Nelson DO, Scott DW (1992) Synergy between TGF-beta and anti-IgM in growth inhibition of CD5+ B-cell lymphomas. Ann N Y Acad Sci 651:274-276
124. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J, et al (1995) Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 85:1063-1074
125. Benjamin D, Park CD, Sharma V (1994) Human B cell interleukin 10. Leuk Lymphoma 12:205-210
126. Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 1289-1298
127. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82:2169-2174
128. Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE, Kaplan MH, Jung B, Espina BM, Lunardi-Iskandar Y, et al (1995) Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423-3430
129. Stewart JP, Behm FG, Arrand JR, Rooney CM (1994) Differential expression of viral and human interleukin-10 (IL- 10) by primary B cell tumors and B cell lines. Virology 200:724-732
130. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK (1993) Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114:218-225; discussion 226
131. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ (1996) The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87: 2594-2603
132. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus- associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191
133. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13
134. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551-555
135. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM (1997) Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549-561